Physician profile
Ben Scheinfeld
NPI 1073565917
$10,785.94
in general payments reported to CMS, 2019-2025
23 companies · $382 in 2025
The $382 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,701 · 2020: $2,107 · 2021: $182 · 2022: $431 · 2023: $439 · 2024: $543 · 2025: $382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,292 · Education: $71.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,292.06 |
| Education | $71.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $7,857.98 | 2019-2025 | Viberzi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $522.59 | 2019-2024 | Entyvio |
| Pfizer INC. | $485.73 | 2019-2025 | |
| Genzyme Corporation | $453.60 | 2022-2025 | |
| Janssen Biotech, INC. | $351.55 | 2019-2025 | Tremfya, Stelara, Simponi |
| Gilead Sciences, INC. | $192.67 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $152.29 | 2019-2024 | Trulance |
| Regeneron Healthcare Solutions, INC. | $123.97 | 2022-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $111.25 | 2019-2022 | |
| Qol Medical, LLC | $81.26 | 2023-2025 | Sucraid, Sucraid |
| Aimmune Therapeutics, INC. | $79.41 | 2023-2024 | |
| Ucb, INC. | $71.84 | 2019 | |
| Intercept Pharmaceuticals, INC. | $45.43 | 2019-2021 | |
| Celgene Corporation | $45.05 | 2022 | |
| Celltrion USA INC. | $41.49 | 2024 | Zymfentra |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $33.68 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $29.45 | 2021-2022 | |
| Glaxosmithkline, LLC. | $26.73 | 2019 | |
| Evoke Pharma, INC. | $20.69 | 2023 | Gimoti |
| Fresenius Kabi USA, LLC | $17.51 | 2023 | Idacio |
| Boston Scientific Corporation | $17.23 | 2025 | General - Pain Management |
| Otsuka America Pharmaceutical, INC. | $13.38 | 2019 | |
| Phathom Pharmaceuticals, INC. | $11.16 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ben Scheinfeld listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.